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Sternotomy with Bilateral Systematic Mediastinal Lymph Node 
Dissection (BSMLD) in patients with lung cancer 
Porhanov, Vladimir A.; Poliakov, Igor S.; Bodnia, Vadim N. 
Regional Cardio-thoracic Surgery Center, Krasnodar, Russia
Aim: Stages III A and III B (with invaded mediastinal lymph nodes) 
are considered to be an contraindication to surgery. This group of 
patients with mediastinal lesions is inhomogeneous, that is why their 
treatment scheme should be selected individually and surgery with 
systematic bilateral mediastinal lymphodissection is its basis.
Materials and Methods: Since 1991 to December 2006, 158 patients 
with NSCLC and mediastinal lymph nodes involvement had been ran-
domized for the study of 6450 operated on patients for lung cancer. All 
of them underwent systematic bilateral mediastinal lymphodissection 
via thoracotomic (T, 81 cases) and sternotomic (S, 77 cases) approach-
es. Mean age was 60,5 years. Nine patients (5.6%) were found to have 
stage cTIIIb. Pneumonectomy was performed in 71% (112 patients), in 
other cases we performed lobe- and bilobectomies. Minimal follow-up 
was 3 months. 
Results: Postoperatively Stage pTIIIb was found in 27 (17%) cases 
- in 6 patients operated on via thoracotomy (7,4%), and in 21 patients 
operated on via sternotomy (27%) (s.d.). Postoperative complications 
were found in 8,6% patients in group T and in 7.7% patients in group S 
(n.s.). Mortality rate was 2,3% è 2,6% (n.s.). Five-year survival rate for 
N2 was 14% (T) versus 28% (S) - s.d. Five-year survival rate for N3 
(Ò) was nil, and for group S - 10%.
Conclusions: Systematic bilateral lymphodissection does not worsen 
immediate results of surgical treatment. It enables to make an accurate 
staging and select an optimal mode of the further treatment which re-
sults in reliably increased life-span in patients with invaded mediastinal 
lymph nodes.
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Surgery for Stage III A-B NSCLC (with mediastinal lymph nodes 
involvement)
Porhanov, Vladimir A.; Poliakov, Igor S.; Kononenko, Valery B.;  
Kovalenko, Alexey L.; Bodnia, Vadim N. 
Regional Cardio-thoracic Surgery Center, Krasnodar, Russia
Aim: Stages III A and III B (with invaded mediastinal lymph nodes) 
are considered to be an contraindication to surgery. This group of 
patients with mediastinal lesions is inhomogeneous, that is why their 
treatment scheme should be selected individually and surgery with 
systematic bilateral mediastinal lymphodissection is its basis.
Materials and Methods: Since 1991 to December 2006, 158 patients 
with NSCLC and mediastinal lymph nodes involvement had been ran-
domized for the study of 6450 operated on patients for lung cancer. All 
of them underwent systematic bilateral mediastinal lymphodissection 
via thoracotomic (T, 81 cases) and sternotomic (S, 77 cases) approach-
es. Mean age was 60,5 years. Nine patients (5.6%) were found to have 
stage cTIIIb. Pneumonectomy was performed in 71% (112 patients), in 
other cases we performed lobe- and bilobectomies. Minimal follow-up 
was 3 months. 
Results: Postoperatively Stage pTIIIb was found in 27 (17%) cases 
- in 6 patients operated on via thoracotomy (7,4%), and in 21 patients 
operated on via sternotomy (27%) (s.d.). Postoperative complications 
were found in 8,6% patients in group T and in 7.7% patients in group S 
(n.s.). Mortality rate was 2,3% è 2,6% (n.s.). Five-year survival rate for 
N2 was 14% (T) versus 28% (S) - s.d. Five-year survival rate for N3 
(Ò) was nil, and for group S - 10%.
Conclusions: Systematic bilateral lymphodissection does not worsen 
immediate results of surgical treatment. It enables to make an accurate 
staging and select an optimal mode of the further treatment which re-
sults in reliably increased life-span in patients with invaded mediastinal 
lymph nodes.
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Tumor size as a prognostic factor for the survival of surgically 
treated stage Ia non-small cell carcinoma
Lyons, Gustavo A.1 Quadrelli, Silvia2 Chimondeguy, Domingo J.2 Iotti, 
Alejandro2 Silva, Carlos2 Vera, Karina2 
1 Hospital Británico de Buenos Aires, Buenos Aires, Argentina 2 Hospi-
tal Británico de Buenos Aires, Ciudad de Buenos Aires, Argentina 
Objective: TNM stage is an important predicting long-term survival 
of lung cancer patients. Some studies have shown, however, that tumor 
size may have intrinsic prognostic value independent of TNM stage. 
The relationship between tumor size and survival is particularly unclear 
in T1 tumors. The objective of this study was to assess the prognostic 
value of tumor size in surgically resected stage I non-small cell lung 
cancer (NSCLC) .
Methods: From 1995 to 2006, 79 patients received curative lung resec-
tions and mediastinal linphadenectomy for stage IA NSCLC. In 34.4% 
of patients (n = 28) tumor size was ? 1.5 cm. Surgical mortality was 
1.3%. Disease recurrence was noted in 19%. 
Results: Patients with tumors ? 15mm had a signiﬁcantly higher 5-year 
survival (95% CI:0.05 vs 77% CI:0.07 in > 15mm group). Disease-free 
survival was 95% for tumors less than 15 mm vs 72% in larger tumors. 
Using Cox Multivariate analysis, the most determinant factor for higher 
risk of mortality was size >15 mm (relative risk 25.9 IC: 2.3-292, p = 
0.004). 
Conclusions: The independent inﬂuence of tumor size in stage IA 
NSCLC may have practical implications in regards to proposals for 
screening asymptomatic individuals at high risk for lung cancer
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The prognostic value of the Standardized Uptake Value (SUV) of 
FDG-PET in patients with stage I and II non-small cell lung cancer 
(NSCLC) treated by radical surgery
Rops, Maria J.; Maas, Klaartje W.; Schramel, Franz M.; Verzijlbergen, 
Fred J. 
St. Antonius Hospital, Nieuwegein, The Netherlands
Introduction: Patients with stage I or II NSCLC are candidates for 
surgery, resulting in 5-year survival ranging from 40 to 70%. How-
ever, even in resected stage I NSCLC, recurrence accounts for 57% 
of deaths! FDG-PET has become standard procedure in the diagnostic 
work-up of patients with (suspected) NSCLC. The aim of this study 
was to analyse the prognostic value of SUV of FDG-PET in patients 
with radical resected stage I and II NSCLC.
Methods: Primary endpoint of this retrospective study was time to 
recurrence after radical resection of stage I and II NSCLC in relation to 
the SUV on FDG-PET, pre-operatively used for staging purpose. Sec-
ondary endpoints were stage at presentation, histology, tumour size, oc-
currence of metastases during follow-up and overall survival in relation 
to the SUV. Statistics were performed by t-test and Kruskal-Wallis test.
Results: From the period of May 2003 until January 2005, 53 pa-
tients with radical resected stage I or II NSCLC were included. In 18 
patients who developed a recurrence, a strong inverse correlation was 
seen between SUV and time to recurrence (R=0.61; p<0.005), with a 
cut-off value of 7.0. There was no signiﬁcant relation between SUV 
with tumour size, histology, and the occurrence of metastases or overall 
survival. Patients with stage IIB NSCLC showed signiﬁcant higher 
SUV than patients with stage I NSCLC.
Conclusion: SUV of FDG-PET shows prognostic signiﬁcance in pre-
dicting the time to recurrence of radical resected stage I and II NSCLC. 
Prospective studies are needed to validate this predictive value. SUV 
could play an important role in the decision whether or not to treat 
patients after radical pulmonary resection for stage I or II NSCLC with 
adjuvant chemotherapy.
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Comparison of 5-year survival rate in surgically treated IB and IIA 
NSCLC patients
Rudzinski, Piotr M.; Kupis, Wlodzimierz R.; Orlowski, Tadeusz M. 
National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
Background: The group of patients operated on for N1 NSCLC is 
considered very heterogeneous in terms of 5-year survival rates.
Therefore we have decided to compare 5-year survival rates operated 
on at our institution for NSCLC in pathological stage of T2N0 and 
T1N1.
Methods: We reviewed retrospectively the data of 696 patients who 
underwent the lung resection for NSCLC in our institution between 
January 1998 and December 2000. In all of them the complete lymph-
adenectomy (hilar and mediastinal) was performed along with lung 
resection.
Results: The stage of the disease was estimated as IB in 181 pts 
(26,6%) and as IIA in 44 pts (6,3%). (N1 was conﬁrmed in 221pts out 
of 696 operated on). 5-year survival rate in IB and IIA groups was 61% 
and 54,5% respectively. We accepted the p value < 0,001 in log rank 
test as the statistically signiﬁcant.
We have found no statistically signiﬁcant inﬂuence of age (59,4% in 
<50 year old pts and 59,4% in >70y old pts, p<0.55), type of resection 
(63,8% in lobectomy, 56,3% in pneumonectomy, p<0.69), histology 
(59,7% in adenocarcinoma, 61,3% in squamous cell, p=0,93), T value 
(p=0.66), presence of neoplastic tromboli in lymphatic vessels (50% of 
positive, 61,1% if negative, p< 0,34) or inﬁltration of nerves (61% if 
negative, 47,1% if positive, p<0,28) on 5-year survival rate.
Among patient with N1 there was no statistically signiﬁcant differ-
ence between hilar and intrapulmonary lymphatic spread - the 5-year 
survival rate was 60,9% and 52,7% respectively (p<0,32). Each of 
these two groups of hilar lymphnodes were divided into two subgroups. 
There was also no statistically signiﬁcant difference within both of 
them. In hilar lymphnodes - groups 10 and 11 - the 5-year survival rate 
was 60.9% and 52.7% (p < 0.32) respectively and in intrapulmonary 
lymphnodes - groups 12 and 13 - 5-year survival rate was 51.5% and 
48.3% (p<0.56) respectively.
Marginal statistically signiﬁcant inﬂuence on 5-year survival rate we 
found comparing the sex of patients (M -55,1%, F - 61,1,%, p < 0,01) 
and presence of neoplastic emboli in blood vessels (52,6% if positive 
and 64,4% if negative, p < 0.08).
Conclusions: The lack of statistically signiﬁcant differences between 
these two groups of patients let us suggest combining them into one 
group.
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What are the factors that determine prognosis of recurrent non-
small cell lung cancer after curative surgery?
Sakuragi, Tohru; Furutachi, Akira; Mitsuoka, Masahiro; Itoh, Tsuyoshi 
Thoracic and Cardivascular Surgery, Saga University, Saga, Japan
Objective: Recurrence of non-small cell lung cancer (NSCLC) after 
surgery is difﬁcult to prevent. Although many cases are fatal within a 
short time period, other individuals survive for long periods after the 
recurrence. The aim of this study was to investigate the factors that 
inﬂuence prognosis of recurrent NSCLC.
